Webinar:  CLIA IQCP: Difference from Standard QC Approach, Requirements and Laboratory Compliance

UCB

UCBUCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). For more information, please visit www.ucb.com

UCB RSS Channel

Title Filter      Display #  
# Article Title
1 UCB and Biogen Idec enter agreement to commercialize multiple sclerosis and hemophilia therapies in Asia
2 Multimillion pound investment in UK life sciences research and development
3 Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
4 UCB announces regulatory filings for Cimzia® (certolizumab pegol)
5 Accelerating focus on the patient
6 UCB announces third research collaboration with Harvard University
7 UCB half year results 2012: on track for growth
8 UCB expands in Brazil
9 UCB marks World Parkinson's Disease Day with new Parkinson's Well-Being Map™
10 Neupro® approved by U.S. FDA for Parkinson's disease and Restless Legs Syndrome
11 Positive top-line result for UCB's Cimzia® in psoriatic arthritis
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]